CDK4/6 inhibition in cancer: beyond cell cycle arrest
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have recently
entered the therapeutic armamentarium of clinical oncologists, and show promising activity …
entered the therapeutic armamentarium of clinical oncologists, and show promising activity …
Mechanisms of sensitivity and resistance to CDK4/6 inhibition
M Álvarez-Fernández, M Malumbres - Cancer cell, 2020 - cell.com
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …
patients with advanced hormone-positive breast cancer. The efficacy of this strategy is …
Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19
The prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with
aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a …
aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a …
[HTML][HTML] Selective inhibition of CDK4/6: A safe and effective strategy for develo** anticancer drugs
K Yuan, X Wang, H Dong, W Min, H Hao… - … Pharmaceutica Sinica B, 2021 - Elsevier
The sustained cell proliferation resulting from dysregulation of the cell cycle and activation of
cyclin-dependent kinases (CDKs) is a hallmark of cancer. The inhibition of CDKs is a highly …
cyclin-dependent kinases (CDKs) is a hallmark of cancer. The inhibition of CDKs is a highly …
Development of CDK4/6 inhibitors: a five years update
The inhibition of cyclin dependent kinases 4 and 6 plays a role in aromatase inhibitor
resistant metastatic breast cancer. Three dual CDK4/6 inhibitors have been approved for the …
resistant metastatic breast cancer. Three dual CDK4/6 inhibitors have been approved for the …
Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)
SK Pal, J Patel, M He, B Foulk, K Kraft, DA Smirnov… - Cancer, 2018 - Wiley Online Library
BACKGROUND Two androgen receptor (AR)‐targeted therapies, enzalutamide and
abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of …
abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of …
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
KJ Andreano, SE Wardell, JG Baker… - Breast cancer research …, 2020 - Springer
Purpose The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling
pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of …
pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of …
New generation of selective androgen receptor degraders: our initial design, synthesis, and biological evaluation of new compounds with enzalutamide-resistant …
In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel
series of indolyl and indolinyl propanamides (series II and III) were discovered as selective …
series of indolyl and indolinyl propanamides (series II and III) were discovered as selective …
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …
Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
M Ulm, AV Ramesh, KM McNamara… - Endocrine …, 2019 - ec.bioscientifica.com
Hormonal cancers affect over 400,000 men and women, and contribute collectively to over
100,000 deaths in the United States alone. Thanks to advances in the understanding of …
100,000 deaths in the United States alone. Thanks to advances in the understanding of …